|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2017 - Aug 18, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.25|
MISSION VIEJO, CA / ACCESSWIRE / March 23, 2018 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), announced today that it has commenced an out-of-court liquidation conducted by an Assignment for the Benefit ...
- AEOL 10150 Treatment Once Per Day for 60 Days Beginning 24 Hours Post-Exposure Reduced Mortality by 50 Percent - AEOL 10150 Is The Only Drug in Advanced Development by The US Government to Address the ...
AEOL 10150 treatment once per day for 60 days beginning 24 hours post-exposure: - significantly improved survival at 180 Days - delayed onset of lethal effects by 90 days - Increased mean survival at 360 ...
Exposure to the Nerve Agent Surrogate Pilocarpine Causes Prolonged Seizures (Status Epilepticus) that Result in Significant Oxidative Stress Status Epilepticus Induced Oxidative Stress Causes Brain Damage, ...
Single dose well tolerated up to 75 mg No serious adverse events reported No neurological or cardiovascular irregularities reported Analysis and Modeling of PK data suggests: 75 to 125 mg dose for Lung ...
MISSION VIEJO, CA / ACCESSWIRE / August 14, 2017 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, ...